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Summary  The  most  common  manifestation  of  HIV  in  the  kidney  is  HIV-associated
nephropathy  (HIVAN).  In  this  report,  we  describe  the  ﬁrst  documented  case  of  mem-
branous  glomerulonephritis  in  an  HIV-positive  individual  in  Turkey,  the  country  with
the  lowest  HIV  prevalence  in  the  region.  The  case  occurred  in  an  HIV-positive,  hepati-glomerulonephritis tis  C  (HCV)-negative,  and  hepatitis  B  (HBV)-negative  Caucasian  male,  who  presented
with  nephrotic-range  proteinuria.  The  patient  had  a  favorable  response  to  HAART
and  an  angiotensin-receptor  blocker.
©  2012  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.
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tntroductionIV-associated  nephropathy  (HIVAN)  is  character-
zed  clinically  by  proteinuria,  often  with  a  sudden
nset,  with  rapidly  progressive  renal  dysfunction
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oi:10.1016/j.jiph.2011.12.003esulting  in  end-stage  renal  disease  (ESRD)  over
he course  of  several  months  [1].  The  pathology
f HIVAN  is  characterized  by  the  triad  of  collaps-
ng focal  glomerular  sclerosis  (FGS),  microcystic
ubular dilation,  and  endothelial  cell  tubuloretic-
lar inclusions  [2].  HIVAN  was  initially  described
n 1984  by  Rao  et  al.,  who  reported  a  pattern
f sclerosing  glomerulopathy  in  HIV-1-seropositive
atients in  New  York  City  [3].  Although  approx-
mately half  of  the  patients  were  asymptomatic
nd had  not  suffered  from  opportunistic  infections
 Sciences. Published by Elsevier Ltd. All rights reserved.
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at  the  time  of  diagnosis,  all  had  CD4  cell  counts
of less  than  200  cells/mm3.  These  patients  may
present  with  nephrological  disorders.  HIVAN  is  espe-
cially prevalent  among  HIV-1-seropositive  patients
of African  descent  [4,5].  Herein,  we  present  the
ﬁrst well-documented  case  of  an  HIV-1-seropositive
Caucasian  male  patient  with  membranous  glomeru-
lonephritis  but  without  coinfections  associated
with membranous  nephropathy  in  Turkey,  the
country  with  the  lowest  HIV  prevalence  in  the
region.
Case report
A  55-year-old  man  was  admitted  to  our  hospi-
tal with  proteinuria  exceeding  3.5  g  per  day  as
determined  by  urine  analysis  during  a  routine  labo-
ratory evaluation.  He  had  no  further  complaints,
although HIV  seropositivity  had  been  detected  3
months previously.  The  physical  examination  was
normal. Laboratory  ﬁndings  were  as  follows:  Hgb:
11.0 g/dL,  Na:  126  mequiv/L,  albumin:  1.4  g/dL,
creatinine:  1.8  mg/dL,  CD4:  75/mm3,  and  HIV  RNA:
547,000 copies/ml.  He  tested  negative  for  toxo-
plasma,  syphilis  and  malaria.  The  urinary  sediment
revealed  severe  proteinuria.  The  glomerular  ﬁl-
tration rate  (GFR)  was  found  to  be  77  ml/min  as
predicted  by  the  24-h  creatinine  excretion  rate.
Proteinuria  of  6.7  g  per  day  was  detected  by  24-
h measurements  and  urine  analysis.  The  serum
complement  levels  were  normal.  Serum  protein
electrophoresis showed  a  broad-based  increase  in
the levels  of  gamma  globulins.  ANA  was  slightly
positive; cANCA  and  pANCA  were  negative.  The
patient  was  also  negative  for  HCV  and  HBV.  Further
investigation  excluded  malignancies  and  possi-
ble exposure  to  drugs.  Urinary  ultrasonography
revealed  increased  parenchymal  echogenicity  in
the right  kidney.
A renal  biopsy  was  performed,  and  a  total  of
18 glomeruli  were  observed  on  the  slides.  Three
of these  glomeruli  were  globally  sclerotic.  The
other  glomeruli  were  normocellular,  but  the  cap-
illary basement  membranes  were  signiﬁcantly  and
diffusely thickened.  The  mesangial  regions  were
slightly expanded  and  hypercellular  in  some  seg-
ments. The  interstitium  was  expanded  in  the
subcapsular  region  with  mononuclear  cell  inﬁltra-
tion (Fig.  1).  The  histopathological  abnormalities
observed in  the  renal  biopsy  specimen  were  consis-
tent with  membranous  glomerulonephritis.
A treatment  regimen  of  HAART  (consisting  of
lopinavir/ritonavir  + lamivudine  +  zidovudine)  and
valsartan  (40  mg/day)  was  commenced.  A  dietary
o
n
iigure  1  Diffuse  membranous  glomerulonephritis
H&E).
rotein  range  of  0.6—0.8  g/kg/day  was  suggested
s a  further  means  of  reducing  the  proteinuria.
fter 6  weeks  of  treatment,  his  serum  creatinine
evel was  1.28  mg/dL,  and  urine  analysis  revealed
.825  g/day  of  proteinuria.  The  patient  was  dis-
harged for  follow-up.  The  patient  is  currently  in
he second  year  of  treatment  with  15  mg/day  of
rotein in  the  urine,  a  serum  creatinine  level  of
.04 mg/dL,  a GFR  of  110  ml/min,  a  CD4  level  of
50/mm3 and  no  expression  of  HIV  RNA.
iscussion
urkey  has  one  of  the  lowest  prevalences  of
IV/AIDS in  central  Europe.  By  the  end  of  June
009, a total  of  3898  cases  had  been  identiﬁed  in
ur country,  which  has  a population  of  70  million
6].HIV-infected people  exhibit  a  wide  spectrum
f kidney  histopathologies.  Although  HIVAN  is
ow a well-characterized  renal  disease  present-
ng with  collapsing  focal  glomerulosclerosis,  an
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[IV  infection  with  diffuse  membranous  glomerulone
ver-increasing  number  of  other  glomerulopathies
ncluding  amyloidosis,  minimal  change  disease,  dia-
etic nephropathy,  allergic  interstitial  nephritis,
nd  cryoglobulinemia  are  described  in  association
ith HIV  infection  [1,3,7].  Patients  with  HIVAN  usu-
lly present  with  symptoms  of  chronic  renal  failure
ccompanied  by  proteinuria  [1,3,4].
Membranous  nephropathy  has  been  reported
reviously in  HIV-infected  patients  [8,9].  However,
IV-associated  nephropathies  including  membra-
ous glomerulopathy  have  been  recently  reported
o occur  signiﬁcantly  more  frequently  in  individuals
oinfected  with  hepatitis  C  than  in  those  who  are
ot coinfected  [10].  Our  patient  did  not  have  any
oinfections  or  comorbidities  typically  associated
ith membranous  nephropathy.  He  presented  with
assive proteinuria  with  at  least  3  months  of  known
IV seropositivity.  He  was  asymptomatic  and  had  no
etectable opportunistic  infections.  Unfortunately,
he demonstration  of  viral  antigens  could  not  be
erformed  by  electron  microscopy  or  immunoﬂuo-
escence.
Renal echogenicity  may  be  increased  during  the
ltrasonographic  examination  [4].  Both  increased
chogenicity  of  the  right  kidney  and  diffuse  mem-
ranous  glomerulonephritis  were  observed  in  our
ase.
HAART prevents  the  progression  of  HIVAN
o end-stage  renal  failure.  Furthermore,  HAART
ecreases  the  development  of  HIVAN  by  60%
n risk  groups  [4,11,12]. Angiotensin-converting
nzyme  (ACE)  inhibitors  were  also  implicated  in
he prevention  of  HIVAN  in  some  studies  [1,4].
lthough  steroids  may  cause  signiﬁcant  decreases
n serum  creatinine  levels,  recurrences  were
bserved after  the  cessation  of  therapy  [4,13].
e began  to  treat  our  patient  with  both  HAART
nd an  angiotensin-receptor  blocker  and  observed
he regression  of  proteinuria  at  the  6th  week
f follow-up.  No  immunosuppressive  agent  was
sed.
In conclusion,  HIV  infection  can  lead  to  func-
ional and  structural  abnormalities  in  renal  tissue
t any  stage  of  the  disease.  HIV-associated  mem-
ranous  nephropathy  should  be  considered  in
aucasian  patients  with  HIV  infection  complicated
y nephrotic  syndrome  and  renal  failure  even
n the  absence  of  other  coinfections  and  comor-
idities typically  associated  with  membranous
ephropathy.  The  management  of  HIV-associated
idney diseases  requires  close  collaboration  among
nfectious  disease  specialists  and  nephrologists.
ew combination  therapies  including  protease
nhibitors, determination  of  HIV  disease  stage
y viral  load  detection  and  the  management  of
nfections  and  renal  diseases  at  early  stages  are
[itis  209
romising  modalities  in  the  reversal  of progression
o end-stage  renal  failure.
unding
o  funding  sources.
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